Abstract
Amgen will report third-quarter results on November 03, 2026 Post-Mkt; this preview summarizes consensus forecasts for revenue, margins, net profit, and adjusted EPS, compares last quarter’s delivery versus guidance, and highlights key business drivers and analyst views from April 27, 2026 to October 27, 2026.Market Forecast
Consensus for the current quarter points to total revenue of 10.07 billion US dollars, adjusted EPS of 5.79, and EBIT of 4.33 billion US dollars; year over year, revenue is expected to grow by 12.31%, adjusted EPS by 15.54%, and EBIT by 12.68%. Forecasts do not explicitly guide gross margin or net margin, but prior-quarter margin context implies investors are watching whether gross margin can hold near the low-70% range and whether net margin can remain in the mid-20% range.Management’s business mix commentary centers on product sales as the main driver, with “Products” contributing 9.54 billion US dollars last quarter and “Other” 0.52 billion US dollars; investors expect ongoing strength from newer growth drivers and stable core franchises. The most promising area is the cluster of newer growth drivers, which recently accounted for roughly 70% of product sales by some disclosures and grew at a double-digit rate year over year; momentum there is a key swing factor for this quarter’s print.
Last Quarter Review
Amgen delivered revenue of 10.05 billion US dollars last quarter, with a gross profit margin of 72.64%, GAAP net profit attributable to the parent company of 2.38 billion US dollars, a net profit margin of 23.62%, and adjusted EPS of 6.29; on a year-over-year basis, revenue increased by 9.53% and adjusted EPS increased by 4.49%. Quarter on quarter, the net profit attributable to shareholders increased by 30.57%, reflecting operating leverage and disciplined expense control.Main business composition showed product revenue at 9.54 billion US dollars and other revenue at 0.52 billion US dollars, underlining product franchises as the core earnings engine; growth was concentrated in the newer-product portfolio while mature products remained resilient.
Current Quarter Outlook
Main business drivers and margin sensitivity
The company’s revenue base remains concentrated in product sales, and consensus implies another sequentially steady quarter in absolute dollars. With the prior quarter’s gross margin of 72.64%, investors will look for stability around the low-70% area given the pricing, mix, and manufacturing absorption dynamics typical in large-cap biopharma. Net margin held at 23.62% last quarter; to sustain mid-20% net margin, operating expense pacing and mix toward higher-margin therapies will matter more than one-time items.Unit growth and launch trajectories in newer therapies underpin the revenue expansion embedded in the 12.31% year-over-year consensus. To preserve the margin structure while growing, the mix must continue to tilt to higher-value biologics and specialty products. Watch for commentary on inventory normalization and channel dynamics, as even modest movements can affect quarterly gross margin prints within a narrow band.
Most promising growth engines
Consensus and recent disclosures indicate the newer growth drivers are expanding at a double-digit clip and already constitute a substantial share of product sales. If those therapies again outgrow the corporate average, they can offset any softness in more mature brands and keep the consolidated top line tracking near a low-teens growth pace year over year. Given their higher strategic priority and often favorable margin profile, continued uptake in these assets can help maintain adjusted EPS resilience even if operating expenses rise for pipeline advancement.Pipeline readouts and label-expansion updates tied to these growth engines can shape the slope of 2026–2027 revenue contribution. Any positive usage trends in high-prevalence conditions could produce upside to consensus revenue and EBIT this quarter. Conversely, a pause in adoption or access-related headwinds could leave revenue closer to the low end of intra-quarter expectations, given the concentration of growth in a handful of assets.
Key stock-price swing factors this quarter
The first swing factor is whether revenue lands at or above the 10.07 billion US dollars mark with evidence of broad-based contribution beyond a few therapies; a more diversified beat tends to be rewarded. The second is margin quality: investors will parse gross margin for mix and manufacturing signals and scan the P&L for sustainable operating leverage rather than discrete one-offs, using last quarter’s 72.64%/23.62% gross/net margin anchors as reference points. The third is guidance cadence into the next quarter: affirmation of double-digit growth from the newer-product cluster and stable demand for legacy therapies would support the current adjusted EPS trajectory implied by consensus.A supportive capital-allocation message can also influence sentiment. Last quarter’s adjusted EPS of 6.29 outpaced consensus and reflected healthy EBIT of 4.61 billion US dollars; maintaining that earnings power while investing in launches will be read as constructive. Any deviations in reimbursement or pricing environments could quickly change the slope of growth embedded in forecasts.
Analyst Opinions
Across the April 27, 2026 to October 27, 2026 window, published viewpoints tilt bullish. Commentaries emphasize that six key growth drivers have maintained double-digit expansion and now comprise a large share of product revenue, framing a setup for revenue to grow around low teens year over year and for adjusted EPS to expand at a mid-teens clip this quarter. The prevailing view expects Amgen to meet or slightly exceed consensus on revenue and adjusted EPS, with downside risks centered on margin mix and potential access variability rather than demand.Well-known institutional research highlights continued momentum in the growth-driver portfolio and expects quarter-on-quarter stability in gross margin near the low-70% range, supporting EBIT delivery close to the 4.33 billion US dollars estimate. The bullish camp argues that execution on launches and steady performance from core franchises positions the company to sustain double-digit revenue growth into year-end, with incremental upside if uptake accelerates in key indications. Overall, the majority opinion is constructive, anticipating in-line to modestly better results and reinforcing a positive stance into the print.
Comments